LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 50

Suchoptionen

  1. Buch ; Audio / Video: Internetpräsentationen für Architekten und Freiberufler

    Büscher, Dirk

    [Leistungsbild, rechtliche Rahmenbedingungen und Marketingstrategien für Architekturbüros, insbesondere im Hinblick auf die Präsentation im Internet]

    (Wissenschaft auf CD-ROM)

    2001  

    Verfasserangabe von Dirk Büscher
    Serientitel Wissenschaft auf CD-ROM
    Schlagwörter Architektenbüro ; Web Site ; Online-Marketing
    Sprache Deutsch
    Umfang 1 CD-ROM, 12 cm
    Ausgabenhinweis [Elektronische Ressource]
    Verlag Tectum-Verl
    Erscheinungsort Marburg
    Dokumenttyp Buch ; Audio / Video
    ISBN 3828850766 ; 9783828850767
    Datenquelle Katalog der Technische Informationsbibliothek Hannover

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  2. Buch ; Dissertation / Habilitation: Die qualifizierte faktische Konzernierung - eine gelungene Fortbildung des Rechts der GmbH?

    Büscher, Dirk

    (Europäische Hochschulschriften : Reihe 2, Rechtswissenschaft ; 2632)

    1999  

    Verfasserangabe Dirk Büscher
    Serientitel Europäische Hochschulschriften : Reihe 2, Rechtswissenschaft ; 2632
    Schlagwörter Qualifizierter faktischer Konzern ; Haftung ; GmbH ; Deutschland
    Sprache Deutsch
    Umfang XXV, 202 S, 21 cm
    Verlag Lang
    Erscheinungsort Frankfurt am Main u.a.
    Dokumenttyp Buch ; Dissertation / Habilitation
    Dissertation / Habilitation Univ., Diss.--Bochum, 1998
    ISBN 363134726X ; 9783631347263
    Datenquelle Ehemaliges Sondersammelgebiet Küsten- und Hochseefischerei

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  3. Buch ; Dissertation / Habilitation: Untersuchungen zur Rolle der zytosolischen Serin/Threonin-Kinase Raf-1 in der Makrophagenzellinie BAC-1.2F5

    Büscher, Dirk

    1994  

    Verfasserangabe von Dirk Büscher
    Sprache Deutsch
    Umfang 71, [14] S, Ill., graph. Darst
    Ausgabenhinweis [Mikrofiche-Ausg.]
    Dokumenttyp Buch ; Dissertation / Habilitation
    Dissertation / Habilitation Univ., Diss.--Hannover, 1994
    Anmerkung Mikrofiche-Ausg.: 1 Mikrofiche : 24x
    Datenquelle Ehemaliges Sondersammelgebiet Küsten- und Hochseefischerei

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  4. Buch ; Dissertation / Habilitation: Untersuchungen zur Rolle der zytosolischen Serin/Threonin-Kinase Raf-1 in der Makrophagenzellinie BAC-1.2F5

    Büscher, Dirk

    1994  

    Verfasserangabe von Dirk Büscher
    Sprache Deutsch
    Umfang 71 Bl., Anh
    Dokumenttyp Buch ; Dissertation / Habilitation
    Dissertation / Habilitation Univ., Diss.--Hannover, 1994
    Datenquelle Katalog der Technische Informationsbibliothek Hannover

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  5. Artikel: GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2

    Mizrahi, Rena A. / Lin, Wendy Y. / Gras, Ashley / Niedecken, Ariel R. / Wagner, Ellen K. / Keating, Sheila M. / Ikon, Nikita / Manickam, Vishal A. / Asensio, Michael A. / Leong, Jackson / Medina-Cucurella, Angelica V. / Benzie, Emily / Carter, Kyle P. / Chiang, Yao / Edgar, Robert C. / Leong, Renee / Lim, Yoong Wearn / Simons, Jan Fredrik / Spindler, Matthew J. /
    Stadtmiller, Kacy / Wayham, Nicholas / Büscher, Dirk / Terencio, Jose Vicente / Germanio, Clara Di / Chamow, Steven M. / Olson, Charles / Pino, Paula A. / Park, Jun-Gyu / Hicks, Amberlee / Ye, Chengjin / Garcia-Vilanova, Andreu / Martinez-Sobrido, Luis / Torrelles, Jordi B. / Johnson, David S. / Adler, Adam S.

    Pathogens. 2022 July 19, v. 11, no. 7

    2022  

    Abstract: Conventionally, hyperimmune globulin drugs manufactured from pooled immunoglobulins from vaccinated or convalescent donors have been used in treating infections where no treatment is available. This is especially important where multi-epitope ... ...

    Abstract Conventionally, hyperimmune globulin drugs manufactured from pooled immunoglobulins from vaccinated or convalescent donors have been used in treating infections where no treatment is available. This is especially important where multi-epitope neutralization is required to prevent the development of immune-evading viral mutants that can emerge upon treatment with monoclonal antibodies. Using microfluidics, flow sorting, and a targeted integration cell line, a first-in-class recombinant hyperimmune globulin therapeutic against SARS-CoV-2 (GIGA-2050) was generated. Using processes similar to conventional monoclonal antibody manufacturing, GIGA-2050, comprising 12,500 antibodies, was scaled-up for clinical manufacturing and multiple development/tox lots were assessed for consistency. Antibody sequence diversity, cell growth, productivity, and product quality were assessed across different manufacturing sites and production scales. GIGA-2050 was purified and tested for good laboratory procedures (GLP) toxicology, pharmacokinetics, and in vivo efficacy against natural SARS-CoV-2 infection in mice. The GIGA-2050 master cell bank was highly stable, producing material at consistent yield and product quality up to >70 generations. Good manufacturing practices (GMP) and development batches of GIGA-2050 showed consistent product quality, impurity clearance, potency, and protection in an in vivo efficacy model. Nonhuman primate toxicology and pharmacokinetics studies suggest that GIGA-2050 is safe and has a half-life similar to other recombinant human IgG1 antibodies. These results supported a successful investigational new drug application for GIGA-2050. This study demonstrates that a new class of drugs, recombinant hyperimmune globulins, can be manufactured consistently at the clinical scale and presents a new approach to treating infectious diseases that targets multiple epitopes of a virus.
    Schlagwörter Severe acute respiratory syndrome coronavirus 2 ; cell growth ; cell lines ; drugs ; epitopes ; half life ; humans ; immunoglobulin G ; microfluidic technology ; models ; monoclonal antibodies ; neutralization ; pharmacokinetics ; product quality ; sequence diversity ; therapeutics ; toxicology ; viruses
    Sprache Englisch
    Erscheinungsverlauf 2022-0719
    Erscheinungsort Multidisciplinary Digital Publishing Institute
    Dokumenttyp Artikel
    ZDB-ID 2695572-6
    ISSN 2076-0817
    ISSN 2076-0817
    DOI 10.3390/pathogens11070806
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel: Biodistribution and Efficacy of Human Adipose-Derived Mesenchymal Stem Cells Following Intranodal Administration in Experimental Colitis.

    Lopez-Santalla, Mercedes / Mancheño-Corvo, Pablo / Escolano, Amelia / Menta, Ramon / DelaRosa, Olga / Abad, Jose Luis / Büscher, Dirk / Redondo, Juan M / Bueren, Juan A / Dalemans, Wilfried / Lombardo, Eleuterio / Garin, Marina I

    Frontiers in immunology

    2017  Band 8, Seite(n) 638

    Abstract: Mesenchymal stem cells (MSCs) have a large potential in cell therapy for treatment of inflammatory and autoimmune diseases, thanks to their immunomodulatory properties. The encouraging results in animal models have initiated the translation of MSC ... ...

    Abstract Mesenchymal stem cells (MSCs) have a large potential in cell therapy for treatment of inflammatory and autoimmune diseases, thanks to their immunomodulatory properties. The encouraging results in animal models have initiated the translation of MSC therapy to clinical trials. In cell therapy protocols with MSCs, administered intravenously, several studies have shown that a small proportion of infused MSCs can traffic to the draining lymph nodes (LNs). This is accompanied with an increase of different types of regulatory immune cells in the LNs, suggesting the importance of migration of MSCs to the LNs in order to contribute to immunomodulatory response. Intranodal (IN), also referred as intralymphatic, injection of cells, like dendritic cells, is being proposed in the clinic for the treatment of cancer and allergy, showing that this route of administration is clinically safe and efficient. In this study, we investigated, for the first time, the biodistribution and the efficacy of Luciferase
    Sprache Englisch
    Erscheinungsdatum 2017
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2606827-8
    ISSN 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2017.00638
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel: Intralymphatic Administration of Adipose Mesenchymal Stem Cells Reduces the Severity of Collagen-Induced Experimental Arthritis.

    Mancheño-Corvo, Pablo / Lopez-Santalla, Mercedes / Menta, Ramon / DelaRosa, Olga / Mulero, Francisca / Del Rio, Borja / Ramirez, Cristina / Büscher, Dirk / Bueren, Juan A / Lopez-Belmonte, Juan / Dalemans, Wilfried / Garin, Marina I / Lombardo, Eleuterio

    Frontiers in immunology

    2017  Band 8, Seite(n) 462

    Abstract: Mesenchymal stem cells (MSCs) are multipotent stromal cells with immunomodulatory properties. They have emerged as a very promising treatment for autoimmunity and inflammatory diseases such as rheumatoid arthritis. Previous studies have demonstrated that ...

    Abstract Mesenchymal stem cells (MSCs) are multipotent stromal cells with immunomodulatory properties. They have emerged as a very promising treatment for autoimmunity and inflammatory diseases such as rheumatoid arthritis. Previous studies have demonstrated that MSCs, administered systemically, migrate to lymphoid tissues associated with the inflammatory site where functional MSC-induced immune cells with a regulatory phenotype were increased mediating the immunomodulatory effects of MSCs. These results suggest that homing of MSCs to the lymphatic system plays an important role in the mechanism of action of MSCs
    Sprache Englisch
    Erscheinungsdatum 2017
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2606827-8
    ISSN 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2017.00462
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  8. Artikel ; Online: Endoscopic submucosal injection of adipose-derived mesenchymal stem cells ameliorates TNBS-induced colitis in rats and prevents stenosis.

    Martín Arranz, Eduardo / Martín Arranz, María Dolores / Robredo, Tomás / Mancheño-Corvo, Pablo / Menta, Ramón / Alves, Francisco Javier / Suárez de Parga, Jose Manuel / Mora Sanz, Pedro / de la Rosa, Olga / Büscher, Dirk / Lombardo, Eleuterio / de Miguel, Fernando

    Stem cell research & therapy

    2018  Band 9, Heft 1, Seite(n) 95

    Abstract: Background: Mesenchymal stem cells have potential applications in inflammatory bowel disease due to their immunomodulatory properties. Our aim was to evaluate the feasibility, safety and efficacy of endoscopic administration of adipose-derived ... ...

    Abstract Background: Mesenchymal stem cells have potential applications in inflammatory bowel disease due to their immunomodulatory properties. Our aim was to evaluate the feasibility, safety and efficacy of endoscopic administration of adipose-derived mesenchymal stem cells (ASCs) in a colitis model in rats.
    Methods: Colitis was induced in rats by rectal trinitrobenzenesulfonic acid (TNBS). After 24 h ASCs (10
    Results: Endoscopic injection was successful in all the animals. No significant adverse events or mortality due to the procedure occurred. Weight evolution was significantly better in the ASC group, recovering initial weight by day 11 (- 0.8% ± 10.1%, mean ± SD), whereas the vehicle group remained in weight loss (- 6.7% ± 9.2%, p = 0.024). The endoscopic score improved in the ASC group by 47.1% ± 5.3% vs. 21.8% ± 6.6% in the vehicle group (p < 0.01). Stenosis was less frequent in the ASC group (4.8% vs. 41.2%, p < 0.01). Colon length significantly recovered in the ASC group versus the vehicle group (222.6 ± 17.3 mm vs. 193.6 ± 17.9 mm, p < 0.001). The endoscopic score significantly correlated with weight change, macroscopic necropsy score and colon length. Foxp3 and IL-10 mRNA levels in MLN recovered with ASC treatment.
    Conclusions: ASC submucosal endoscopic injection is feasible, safe and ameliorates TNBS-induced colitis in rats, especially stenosis.
    Mesh-Begriff(e) Adipose Tissue/cytology ; Animals ; Cells, Cultured ; Colitis, Ulcerative/etiology ; Colitis, Ulcerative/pathology ; Colitis, Ulcerative/therapy ; Constriction, Pathologic ; Humans ; Male ; Mesenchymal Stem Cell Transplantation/methods ; Rats ; Rats, Sprague-Dawley ; Trinitrobenzenesulfonic Acid/toxicity
    Chemische Substanzen Trinitrobenzenesulfonic Acid (8T3HQG2ZC4)
    Sprache Englisch
    Erscheinungsdatum 2018-04-10
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2548671-8
    ISSN 1757-6512 ; 1757-6512
    ISSN (online) 1757-6512
    ISSN 1757-6512
    DOI 10.1186/s13287-018-0837-x
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  9. Artikel ; Online: Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses.

    González, Manuel A / Gonzalez-Rey, Elena / Rico, Laura / Büscher, Dirk / Delgado, Mario

    Gastroenterology

    2009  Band 136, Heft 3, Seite(n) 978–989

    Abstract: Background & aims: Crohn's disease is a chronic disease characterized by severe T-helper (Th)1 cell-driven inflammation of the colon partially caused by a loss of immune tolerance against mucosal antigens. Mesenchymal stem cells were recently described ... ...

    Abstract Background & aims: Crohn's disease is a chronic disease characterized by severe T-helper (Th)1 cell-driven inflammation of the colon partially caused by a loss of immune tolerance against mucosal antigens. Mesenchymal stem cells were recently described to suppress effector T-cell responses and have therapeutic effects in some immune disorders. Here, we investigated the potential therapeutic effects of human adipose-derived mesenchymal stem cells (hASCs) in a model of inflammatory bowel disease.
    Methods: Mice with trinitrobenzene sulfonic acid-induced colitis were treated with hASCs after onset of disease and clinical scores were evaluated. Inflammatory response was determined by measuring the levels of different inflammatory mediators in colon and serum. Th1-mediated effector responses were evaluated by determining the proliferation and cytokine profile of activated mesenteric lymph node cells. The number of regulatory T cells and the suppressive capacity on Th1 cell responses was determined.
    Results: Systemic infusion of hASCs or murine ASCs ameliorated the clinical and histopathologic severity of colitis, abrogating body weight loss, diarrhea, and inflammation and increasing survival (P < .001). This therapeutic effect was mediated by down-regulating both Th1-driven autoimmune and inflammatory responses. ASCs decreased a wide panel of inflammatory cytokines and chemokines and increased interleukin-10 levels (P < .001), directly acting on activated macrophages. hASCs also impaired Th1 cell expansion and induced/activated CD4(+)CD25(+)FoxP3(+) regulatory T cells with suppressive capacity on Th1 effector responses in vitro and in vivo (P < .001).
    Conclusions: hASCs emerge as key regulators of immune tolerance and as attractive candidates for a cell-based therapy for Crohn's disease.
    Mesh-Begriff(e) Adipose Tissue/cytology ; Animals ; Autoimmunity ; Cells, Cultured ; Colitis/immunology ; Colitis/pathology ; Colitis/therapy ; Crohn Disease/immunology ; Crohn Disease/pathology ; Crohn Disease/therapy ; Disease Models, Animal ; Down-Regulation/immunology ; Humans ; Immune Tolerance ; Mesenchymal Stem Cell Transplantation ; Mesenchymal Stromal Cells/cytology ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; T-Lymphocytes, Regulatory/immunology ; Th1 Cells/immunology
    Sprache Englisch
    Erscheinungsdatum 2009-03
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80112-4
    ISSN 1528-0012 ; 0016-5085
    ISSN (online) 1528-0012
    ISSN 0016-5085
    DOI 10.1053/j.gastro.2008.11.041
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ui V Zs.44: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 572: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  10. Artikel: Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells.

    González, Manuel A / Gonzalez-Rey, Elena / Rico, Laura / Büscher, Dirk / Delgado, Mario

    Arthritis and rheumatism

    2009  Band 60, Heft 4, Seite(n) 1006–1019

    Abstract: Objective: Rheumatoid arthritis (RA) is a chronic autoimmune disease caused by loss of immunologic self tolerance and characterized by chronic joint inflammation. Adult mesenchymal stem cells (MSCs) were recently found to suppress effector T cell ... ...

    Abstract Objective: Rheumatoid arthritis (RA) is a chronic autoimmune disease caused by loss of immunologic self tolerance and characterized by chronic joint inflammation. Adult mesenchymal stem cells (MSCs) were recently found to suppress effector T cell responses and to have beneficial effects in various immune disorders. The purpose of this study was to examine a new therapeutic strategy for RA based on the administration of human adipose-derived MSCs (AD-MSCs).
    Methods: DBA/1 mice with collagen-induced arthritis were treated with human AD-MSCs after disease onset, and clinical scores were determined. Inflammatory response was determined by measuring the levels of different mediators of inflammation in the joints and serum. The Th1-mediated autoreactive response was evaluated by determining the proliferative response and cytokine profile of draining lymph node cells stimulated with the autoantigen. The number of Treg cells and the suppressive capacity on self-reactive Th1 cells were also determined.
    Results: Systemic infusion of human AD-MSCs significantly reduced the incidence and severity of experimental arthritis. This therapeutic effect was mediated by down-regulating the 2 deleterious disease components: the Th1-driven autoimmune and inflammatory responses. Human AD-MSCs decreased the production of various inflammatory cytokines and chemokines, decreased antigen-specific Th1/Th17 cell expansion, and induced the production of antiinflammatory interleukin-10 in lymph nodes and joints. Human AD-MSCs also induced de novo generation of antigen-specific CD4+CD25+FoxP3+ Treg cells with the capacity to suppress self-reactive T effector responses.
    Conclusion: Human AD-MSCs emerge as key regulators of immune tolerance by inducing the generation/activation of Treg cells and are thus attractive candidates for a cell-based therapy for RA.
    Mesh-Begriff(e) Adipose Tissue/cytology ; Animals ; Arthritis, Experimental/immunology ; Arthritis, Experimental/therapy ; Arthritis, Rheumatoid/immunology ; Arthritis, Rheumatoid/therapy ; CD4 Antigens/metabolism ; Disease Models, Animal ; Down-Regulation/immunology ; Forkhead Transcription Factors/metabolism ; Humans ; Immune Tolerance/immunology ; Interleukin-2 Receptor alpha Subunit/metabolism ; Lymphocyte Count ; Mesenchymal Stem Cell Transplantation ; Mice ; Mice, Inbred C57BL ; Mice, Inbred DBA ; T-Lymphocytes, Regulatory/cytology ; T-Lymphocytes, Regulatory/immunology ; T-Lymphocytes, Regulatory/metabolism ; Th1 Cells/cytology ; Th1 Cells/immunology ; Th1 Cells/metabolism ; Transplantation, Heterologous
    Chemische Substanzen CD4 Antigens ; Forkhead Transcription Factors ; Foxp3 protein, mouse ; Interleukin-2 Receptor alpha Subunit
    Sprache Englisch
    Erscheinungsdatum 2009-04
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 127294-9
    ISSN 1529-0131 ; 0004-3591 ; 2326-5191
    ISSN (online) 1529-0131
    ISSN 0004-3591 ; 2326-5191
    DOI 10.1002/art.24405
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 24: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 523: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang